



Media Release

20 October 2010

PHARMAXIS CHIEF EXECUTIVE OFFICER RESUMES OFFICE

The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley is pleased to advise that Dr Alan Robertson has today resumed the role of Chief Executive Officer after a period of medical leave.

Mr Hanley said, "Dr Robertson has made a full recovery and we welcome him back. The Board wishes to acknowledge the leadership provided in Alan's absence by the management team, particularly Mr Gary Phillips, our Chief Operating Officer."

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: David McGarvey – Company Secretary

Ph: +61 2 9454 7200 or email david.mcgarvey@pharmaxis.com.au

RELEASED THROUGH:

Australia:

Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and ASM8 and PXS4159 for asthma. Founded in 1998, Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval.